OSLO, Norway, Aug. 9, 2022 /PRNewswire/ -- On
August 9, 2022, Asieris
Pharmaceuticals, a global biopharmaceutical company specializing in
the discovery and development of innovative drugs for the treatment
of genitourinary tumors and other major diseases, announced that
the multinational Phase III Clinical Trial of APL-1702
(Cevira®), a novel non-surgical treatment of cervical
high-grade squamous intraepithelial lesions (HSIL), has
successfully enrolled 402 patients in the study two months ahead of
schedule. Additionally, Photocure received a $1 million milestone payment from Asieris related
to the ongoing clinical development of Cevira.
APRICITY is a multicenter, prospective, double-blind, randomized
controlled Phase III study further evaluating the efficacy and
safety of the integrated drug-and light-delivery device
Cevira® in the treatment of HSIL. The clinical trial was
approved by the National Medical Products Administration (NMPA) in
July 2020 and was conducted
simultaneously at 65 sites in 8 countries including China, Germany, Hungary and the
Netherlands. The first patient was dosed in November 2020.
Cervical cancer is the fourth most common cancer in women
worldwide1. In 2020, 604,000 new cases and 342,000
deaths worldwide were attributed to cervical cancer.1,2
Current treatments of HSIL of the cervix are based on invasive
surgical interventions, compromising cervical competence and
functionality. Currently, no non-surgical approach is available for
the treatment of precancerous cervical lesions.
Read Asieris' full press release
here: https://asieris.com/asieris-multinational-phase-iii-clinical-trial-for-the-non-surgical-treatment-of-hsil-has-completed-enrollment/
1. Cervical cancer. Available from:
https://www.who.int/health-topics/cervical-cancer
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I,
Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates
of incidence and mortality worldwide for 36 cancers in 185
countries. CA Cancer J Clin. 2021;71(3):209-49
Note to editors:
All trademarks mentioned in this release are protected by law
and are registered trademarks of Photocure ASA
About Cevira®:
Cevira is a breakthrough photodynamic drug-device combination
product that is being developed for non-surgical treatment of
high-grade precancerous lesions of the cervix. Cevira holds the
potential to serve the high unmet medical need for non-invasive
treatment options for patients with HSIL in an outpatient setting,
especially for young women of reproductive age. Asieris
Pharmaceuticals entered into a license agreement with Photocure ASA
(Photocure, PHO: OSE) to obtain the worldwide development and
commercialization of Cevira in July
2019. Cevira® is a registered trademark of
Photocure ASA, based in Oslo,
Norway.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com, www.hexvix.com,
www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/photocure-partner-asieris-announces-completion-of-patient-enrollment-in-cevira-phase-iii-clinical-tr,c3611702
The following files are available for download:
|
https://mb.cision.com/Main/17498/3611702/1612840.pdf
|
Release
|